May 24, 2022 Clinical Research/Diagn. Data at the 2022 ASCO Annual Meeting highlight Roche’s continued commitment to innovation in oncology and personalised healthcare Read more
May 24, 2022 Clinical Research/Diagn. Data at the 2022 ASCO Annual Meeting highlight Roche’s continued commitment to innovation in oncology and personalised healthcare Read more
May 24, 2022 Clinical Research/Diagn. Data at the 2022 ASCO Annual Meeting highlight Roche’s continued commitment to innovation in oncology and personalised healthcare Read more
May 12, 2022 Clinical Research/Diagn. Licensing, IP, and Legal M&A, Partnerships Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure Read more
May 11, 2022 Bio/Pharma/CRO [Ad hoc announcement pursuant to Art. 53 LR] Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer Read more
May 10, 2022 Uncategorized Roche pledges to extend commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028 Read more
April 29, 2022 Licensing, IP, and Legal Product Launch New three-year data for Roche’s Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA) Read more
April 25, 2022 PR/Corporate [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022 Read more
April 22, 2022 Uncategorized CHMP recommends EU approval of Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer Read more
April 22, 2022 Uncategorized CHMP recommends EU conditional approval of Roche’s potential first-in-class bispecific antibody mosunetuzumab for people with relapsed or refractory follicular lymphoma Read more
